Anti-Cancer Agents in Medicinal Chemistry

(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Michelle Prudhomme  
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France

Back

Anticancer Drug Combinations, How Far We can Go Through?

Author(s): Da-Yong Lu, En-Hong Chen, Hong-Ying Wu, Ting-Ren Lu, Bin Xu, Jian Ding.

Graphical Abstract:


Abstract:

Many clinical cancer therapies are less effective by using one anticancer drug only due to refractory properties of cancer pathogenesis and drug resistance property in advanced cancer patients. A general consensus among clinicians is that anticancer drug cocktail might better control cancer progresses and metastasis than single drug therapeutics in clinical trials. Despite great popularity, the anticancer drug combination dogma has not been established. The complexity of drug combination dogma discovery is more than we can expect now. This article speculates possible routes we can undertake in this matter. The background knowledge of drug combination therapy presently practiced and possible future landscapes and drawbacks of cancer drug combinative therapies are highlighted.

Keywords: Drug combination, drug resistance, neoplasm metastasis, biotherapy, cancer stem cell, personalized cancer therapy.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 17
ISSUE: 1
Year: 2017
Page: [21 - 28]
Pages: 8
DOI: 10.2174/1871520616666160404112028
Price: $58